lithium nephropathy
Conditions
Interventions
Group I: administration of amiloride (20 mg once daily), together with lithium.
Reduction of the lithiumdosage with 1/3 at the start of amiloride. Titration of
the lithiumdosage till the usual targe
Sponsors
Sint Elisabeth Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients on chronic lithium therapy and progressive renal function loss, defined as a plasma creatinine concentration increase of at least 10 umol/l/year during at least 5 years, a correlation coefficient of 0.85 on linear regression analysis and a maximum plasma creatinine value of 200 umol/l.
Exclusion criteria
Exclusion criteria: Inability to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The result of combining lithium with amiloride should be reflected in a change in the course of de plasma creatinine concentration (at least cutting in half the slope of the plasma creatinine concentration) within 9 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Does not apply. | — |
Countries
Netherlands
Outcome results
None listed